Statistics for Supernus Pharmaceuticals (id:6431 SUPN)

Valuation metrics

Market cap

1.95B

Enterprise value

1.60B

Trailing P/E (ttm)

32.94

Forward P/E

18.65

PEG ratio

18.65

Price/Sales (ttm)

2.99

Price/Book (mrq)

1.93

Enterprise Value/Revenue

2.45

Enterprise Value/EBITDA

11.10

Overview

Shares outstanding

55.22M

Float

47.59M

Shares short

6.80M

% Held by insiders

0.05%

% Held by institutions

1.13%

Average volume (10 days)

509.29K

Average volume (90 days)

Price summary

52-Week low

25.53

52-Week high

39.37

52-Week change

23.16%

Beta

0.87

50-Day moving average

33.35

200-Day moving average

30.93

Dividends and splits

Forward annual dividend rate

Forward annual dividend yield

Trailing annual dividend rate

0.00%

Trailing annual dividend yield

0.00

5-Year annual dividend yield

Payout ratio

0.00

Dividend date

Ex-dividend date

Last split factor

2:1

Last split date

Financials

Fiscal year

Fiscal year ends

December 31th, 2023

Most recent quarter (mrq)

September 30th, 2024

Profitability

Profit margin

9.16%

Operating margin

16.12%

Operational effectiveness

Return on assets

2.89%

Return on equity

6.22%

Income statement

Revenue (ttm)

11.88

Revenue per share (ttm)

11.88

Quarterly revenue growth (yoy)

Gross profit (ttm)

523.74M

EBITDA

169.24M

Net income to common (ttm)

59.71M

Diluted EPS (ttm)

1.07

Quarterly earnings growth (yoy)

Balance sheet

Total cash (mrq)

403.21M

Total cash per share (mrq)

7.30

Total debt (mrq)

38.15M

Total Debt/Equity (mrq)

3.79

Current ratio (mrq)

219.50%

Book value per share (mrq)

18.24

Cash flow

Cash flow statement

172.50M

Levered free cash flow (LFCF)

162.93M